NCT06874933 2025-08-12
Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
Clinical Trials
12 trialsNCT06992336 2025-05-28
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT06678230 2024-11-07
Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
The First Hospital of Jilin University
Phase 2 Unknown
NCT06605690 2024-09-20
An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer
The Affiliated Hospital Of Guizhou Medical University
Phase NA Not yet recruiting
NCT06331169 2024-08-30
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Fudan University
Phase 1 Recruiting
NCT06015126 2023-08-29
Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients
Xi'an International Medical Center Hospital
Phase NA Unknown
NCT05206656 2022-11-23
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
Hunan Cancer Hospital
Phase 2 Completed
NCT05558722 2022-09-28
ACNTBC
Xijing Hospital
Phase 2 Unknown
NCT04975451 2021-07-27
ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Guangdong Women and Children Hospital
Phase 2 Unknown
NCT04936295 2021-06-23
Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation
Sun Yat-sen University
Phase 2 Unknown
NCT04764084 2021-02-21
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
Peking University Cancer Hospital & Institute
Phase 1 Unknown
NCT04002284 2020-07-29
Anlotinib in Metastatic HER2 Negative Breast Cancer
ChineseAMS
Phase 2 Completed